Publications | France - IP & M&A | Capital Finance No. 1170
Article written by partners Grégoire Triet and Raphaëlle Dequiré-Portier, and associates Jean-Hyacinthe de Mitry and Bruno Laffont, published in French review Capital Finance, No. 1170, of 3 November 2014.
Between 2010 and 2014, over thirty medicinal drugs, each generating over 1 billion dollars’ worth of turnover (Plavix®, Remicade®, Lipitor®, etc.) saw the patents protecting them fall into the public domain. These medicinal blockbusters then immediately came under the assault of the competition, whose cheaper generic drugs brought about a dramatic fall in sales. This common phenomenon has been baptised “the patent cliff”.